Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. NUS
NUS logo

NUS Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
7.600
Open
7.390
VWAP
7.41
Vol
529.87K
Mkt Cap
354.69M
Low
7.270
Amount
3.93M
EV/EBITDA(TTM)
2.35
Total Shares
48.13M
EV
339.04M
EV/OCF(TTM)
4.22
P/S(TTM)
0.25
Nu Skin Enterprises Inc. develops and distributes a comprehensive line of beauty and wellness solutions in approximately 50 markets worldwide. It has nine segments, consisting of its seven geographic Nu Skin segments - Americas, Southeast Asia/Pacific, Mainland China, Japan, Europe & Africa, South Korea, and Hong Kong/Taiwan - and two Rhyz segments - Manufacturing and Rhyz Other. Its brands include Nu Skin personal care, Pharmanex nutrition and ageLOC anti-aging. Its skin and beauty solutions include acne and blemishes, anti-aging, dark circles and puffiness, discoloration, dry skin, lifting and firming, lines and wrinkles, and oily skin and pores. Its nutrition solutions include bone and joint health, brain and memory, energy and stamina, heart health, immunity support, nail skin and hair health, and women's health. It offers various beauty devices, including ageLOC Rose Gold LumiSpa iO, ageLOC LumiSpa Silicone Head, ageLOC LumiSpa iO Stand and LumiSpa Rose Gold Accent Twin Pack.
Show More

Events Timeline

(ET)
2026-03-09
16:10:00
Nu Skin Appoints Chayce Clark as Chief Operating Officer
select
2026-02-12 (ET)
2026-02-12
16:20:00
Sees FY26 Revenue of $1.35B to $1.50B
select
2026-02-12
16:10:00
Sees Q2 Revenue of $320M to $340M
select
2026-02-12
16:10:00
Nu Skin Reports Q4 Revenue of $370.3M
select
2025-11-06 (ET)
2025-11-06
16:28:39
Nu Skin projects FY25 EPS between $3.15 and $3.25
select
2025-11-06
16:28:12
Nu Skin Projects Q4 EPS Between 25c and 35c
select
2025-11-06
16:27:43
Nu Skin Announces Q3 EPS of 34 Cents, Up from 17 Cents Last Year
select
2025-08-07 (ET)
2025-08-07
16:51:14
Nu Skin sees FY25 EPS $3.05-$3.25
select
2025-08-07
16:48:04
Nu Skin reports Q2 EPS 43c vs. ($2.38) last year
select
2025-05-08 (ET)
2025-05-08
17:11:02
Nu Skin reports Q1 EPS 23c excluding Mavely gain vs. 9c last year
select

News

seekingalpha
5.0
03-09seekingalpha
Nu Skin Appoints New COO to Drive Growth
  • Executive Appointment: Nu Skin Enterprises has appointed Chayce Clark as Chief Operating Officer effective immediately, while he continues to serve as Chief Legal Officer, reflecting the company's confidence in its leadership team and operational strategy.
  • Growth Opportunities: The company highlighted growth potential from the Prysm iO intelligent wellness platform and plans to place 100,000 devices in India by 2026, indicating a strategic focus on emerging markets for expansion.
  • Career Development: Prior to this promotion, Clark served as Vice President, Deputy General Counsel, and General Counsel, and his extensive legal and management experience is expected to enhance the company's operational efficiency and strategic execution.
  • Long-Term Turnaround Potential: While the market remains cautious about Nu Skin's long-term transformation, the company demonstrates potential in new product offerings and market expansion, particularly with its initiatives in India expected to drive future growth.
Benzinga
9.5
02-13Benzinga
Pinterest Misses Q4 Revenue Expectations
  • Revenue Shortfall: Pinterest reported Q4 revenue of $1.32 billion, falling short of analyst expectations of $1.33 billion, indicating competitive pressures that may undermine future investor confidence.
  • Earnings Miss: The company posted adjusted earnings of 67 cents per share, below the anticipated 69 cents, reflecting challenges in profitability that could lead to shareholder scrutiny of management.
  • Significant Stock Decline: Pinterest shares plummeted 19.5% to $14.95 in pre-market trading, a drastic move that may raise concerns about the company's future performance and influence investor decisions.
  • Mixed Market Sentiment: U.S. stock futures showed mixed results, with Dow futures down about 0.2%, reflecting cautious market sentiment potentially linked to Pinterest's earnings report, further exacerbating investor unease.
Benzinga
2.0
02-13Benzinga
Oversold Stocks in Consumer Staples Present Buying Opportunities
  • Oversold Stocks Overview: According to Benzinga Pro, major players in the consumer staples sector, including NU Skin Enterprises Inc, Coty Inc, and Honest Company Inc, have relative strength indices (RSI) near or below 30, indicating they are significantly oversold and may present undervalued buying opportunities for investors.
  • RSI Indicator Analysis: The relative strength index (RSI) serves as a momentum indicator that compares a stock's strength on up days versus down days, helping traders better assess short-term stock performance and make more informed investment decisions amid market fluctuations.
  • Market Opportunity Identification: The identification of oversold stocks in the current market environment offers potential appreciation opportunities for investors, particularly in the consumer staples sector, where investors can capitalize on the rebound potential of these undervalued stocks.
  • Investment Strategy Recommendations: While Benzinga does not provide investment advice, the phenomenon of oversold stocks typically attracts value-seeking traders, suggesting a focus on the subsequent performance of these stocks to evaluate their rebound potential.
Benzinga
9.5
02-13Benzinga
Nu Skin Misses Earnings Expectations, Shares Drop Significantly
  • Disappointing Earnings Report: Nu Skin reported a GAAP diluted EPS of 29 cents, missing the 30-cent analyst estimate, with revenue of $370.32 million falling short of the expected $382.70 million, indicating a decline in market competitiveness.
  • Revenue and Customer Base Decline: The company's revenue decreased by 16.9% year-over-year from $445.55 million to $370.32 million, with a 10% drop in customer base to 748,796, an 11% decrease in paid affiliates to 129,311, and a 19% decline in sales leaders to 30,045, reflecting weak market demand.
  • Margin Improvements Amid Decline: Despite the revenue drop, gross margin improved from 62.7% to 70.7%, and operating margin improved from negative 11.9% to 6.3%, showcasing positive progress in cost control and operational efficiency.
  • Cautious Future Outlook: Nu Skin forecasts first-quarter 2026 revenue between $320 million and $340 million, below the $356.80 million estimate, with full-year revenue projected at $1.35 billion to $1.50 billion, also below expectations, highlighting challenges in returning to growth.
seekingalpha
9.5
02-13seekingalpha
Nu Skin Reports Strong Q4 2025 Earnings and Strategic Growth Plans
  • Significant Earnings Growth: Nu Skin reported an adjusted earnings per share of $1.27 for Q4 2025, reflecting a 51% increase from last year, with total revenue reaching $1.49 billion, indicating strong performance amid strategic transformation and expected enhancement of shareholder value.
  • Launch of Prysm iO Devices: The company aims to place over 100,000 Prysm iO devices by the end of 2026, intending to drive long-term growth through intelligent health data collection, with the expansion into India viewed as a key geographic growth opportunity.
  • Strategic Focus on India: Nu Skin initiated premarket operations in India in November 2025, with a formal market opening anticipated in late 2026, emphasizing local manufacturing as crucial for ensuring product quality and competitive pricing, demonstrating commitment to this market.
  • Strong Financial Management: The company generated $80.3 million in cash flow for 2025, reduced outstanding debt to $224 million, and repurchased $20 million in shares during the year, showcasing robust financial execution and confidence in future growth.
seekingalpha
9.5
02-12seekingalpha
Nu Skin Q4 Earnings Miss Expectations, Shares Drop
  • Disappointing Earnings: Nu Skin reported a Q4 GAAP EPS of $0.29, missing expectations by $0.01, which indicates a decline in profitability and led to a 10.97% drop in share price.
  • Significant Revenue Decline: The company's Q4 revenue of $370.3 million fell 16.9% year-over-year and missed market expectations by $12.4 million, reflecting a trend of weak sales performance.
  • Cautious 2026 Outlook: Nu Skin projects 2026 revenue between $1.35 billion and $1.50 billion, representing a decline of 9% to a growth of 1% compared to 2025, indicating uncertainty in future market conditions.
  • Notable FX Impact: The anticipated foreign exchange impact of approximately 1% for both 2026 and Q1 2026 will further affect the company's overall financial performance, especially amid global market volatility.

Valuation Metrics

The current forward P/E ratio for NU Skin Enterprises Inc (NUS.N) is 7.34, compared to its 5-year average forward P/E of 12.18. For a more detailed relative valuation and DCF analysis to assess NU Skin Enterprises Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
12.18
Current PE
7.34
Overvalued PE
16.79
Undervalued PE
7.56

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
6.05
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
8.96
Undervalued EV/EBITDA
3.14

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
0.63
Current PS
0.31
Overvalued PS
0.96
Undervalued PS
0.29

Financials

AI Analysis
Annual
Quarterly

Whales Holding NUS

C
Castleknight Management LP
Holding
NUS
+27.35%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is NU Skin Enterprises Inc (NUS) stock price today?

The current price of NUS is 7.37 USD — it has decreased -1.21

What is NU Skin Enterprises Inc (NUS)'s business?

Nu Skin Enterprises Inc. develops and distributes a comprehensive line of beauty and wellness solutions in approximately 50 markets worldwide. It has nine segments, consisting of its seven geographic Nu Skin segments - Americas, Southeast Asia/Pacific, Mainland China, Japan, Europe & Africa, South Korea, and Hong Kong/Taiwan - and two Rhyz segments - Manufacturing and Rhyz Other. Its brands include Nu Skin personal care, Pharmanex nutrition and ageLOC anti-aging. Its skin and beauty solutions include acne and blemishes, anti-aging, dark circles and puffiness, discoloration, dry skin, lifting and firming, lines and wrinkles, and oily skin and pores. Its nutrition solutions include bone and joint health, brain and memory, energy and stamina, heart health, immunity support, nail skin and hair health, and women's health. It offers various beauty devices, including ageLOC Rose Gold LumiSpa iO, ageLOC LumiSpa Silicone Head, ageLOC LumiSpa iO Stand and LumiSpa Rose Gold Accent Twin Pack.

What is the price predicton of NUS Stock?

Wall Street analysts forecast NUS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NUS is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is NU Skin Enterprises Inc (NUS)'s revenue for the last quarter?

NU Skin Enterprises Inc revenue for the last quarter amounts to 370.32M USD, decreased -16.89

What is NU Skin Enterprises Inc (NUS)'s earnings per share (EPS) for the last quarter?

NU Skin Enterprises Inc. EPS for the last quarter amounts to 0.29 USD, decreased -139.73

How many employees does NU Skin Enterprises Inc (NUS). have?

NU Skin Enterprises Inc (NUS) has 2800 emplpoyees as of March 11 2026.

What is NU Skin Enterprises Inc (NUS) market cap?

Today NUS has the market capitalization of 354.69M USD.